Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > Arbitration

<< Previous

Bullboard Posts

Next >>

Comment by Genie29jon May 22, 2023 4:06pm

104 Views

Post# 35459310

RE:RE:RE:Arbitration

It's definitely a defining moment for the company and our investments

It's important Replicel wins, but:

What does winning look like? If they get the Asia rights back, then what?

What happens if they win, and the results Shiseido did with their studies are less than ideal? (I.e. not as good as Phase 1). Then what?

someething really positive needs to happen here. They can still settle - there is time. But my question is, "what does winning look like to this audience?"

I ask because I am curious, but also because I'm not sure myself

what I am sure of, is I would really like this stock at $3 a share by end of July